50 signatures reached
To: Government
Medical Cannabis prescribed for Fibromyalgia and Myalgic Encephalomyelitis sufferers
Cannabis is currently a Class B substance, defined as a "drug that has no therapeutic value". I believe that to be untrue, not just from my own collective experience, but from the fact that cannabis based medicines are already made available on the NHS to a select and lucky few at exorbitant costs.
I believe that no one should have to suffer due to unjust, immoral laws and that everyone should have the right to access this natural, safe, effective and inexpensive medicine.
Please allow doctors to prescribe medical Cannabis, for Fibromyalgia and Myalgic Encephalomyelitis sufferers, through the NHS instead of being prescribed medication that has little to no effect.
I believe that no one should have to suffer due to unjust, immoral laws and that everyone should have the right to access this natural, safe, effective and inexpensive medicine.
Please allow doctors to prescribe medical Cannabis, for Fibromyalgia and Myalgic Encephalomyelitis sufferers, through the NHS instead of being prescribed medication that has little to no effect.
Why is this important?
Fibromyalgia and Myalgic Encephalomyelitis sufferers have very little chance of finding any medication to help their condition. There isn't one specific drug designed for treatment of symptoms. Drugs that are prescribed have many damaging side effects and patients show little to no improvement taking them. Many pain killers do not work.
Since 2016, the consumption of products containing CBD has doubled and in the last year the number of consumers increased 100%, from an estimated 125,000 consumers in 2016 to 250,000 in 2017. In the UK, it is estimated that the cannabis market could be worth £10bn.
Although the legal situation for CBD and CBD containing products has eased, the same can not be said for THC, whose only legal medical source is Sativex, a medication produced by the British company, GW Pharmaceutics who are currently the only company in the country to have permits for the cultivation of cannabis and the production of derivative products.
Since 2016, the consumption of products containing CBD has doubled and in the last year the number of consumers increased 100%, from an estimated 125,000 consumers in 2016 to 250,000 in 2017. In the UK, it is estimated that the cannabis market could be worth £10bn.
Although the legal situation for CBD and CBD containing products has eased, the same can not be said for THC, whose only legal medical source is Sativex, a medication produced by the British company, GW Pharmaceutics who are currently the only company in the country to have permits for the cultivation of cannabis and the production of derivative products.
